blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3386509

EP3386509 - USE OF CABERGOLINE IN THE TREATMENT OF EYE DISEASES CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS [Right-click to bookmark this link]
Former [2018/42]USE OF AGONISTS OF TYPE-2 DOPAMINERGIC RECEPTORS IN TREATMENT OF CONDITIONS CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS
[2019/13]
StatusNo opposition filed within time limit
Status updated on  24.07.2020
Database last updated on 29.06.2024
FormerThe patent has been granted
Status updated on  16.08.2019
FormerGrant of patent is intended
Status updated on  26.03.2019
FormerRequest for examination was made
Status updated on  14.09.2018
FormerThe international publication has been made
Status updated on  16.06.2017
Formerunknown
Status updated on  07.02.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Oseka, Maciej
ul. Wspólna 16 G
05-462 Duchnów / PL
[2019/17]
Former [2018/42]For all designated states
Ofta Sp. z.o.o.
Ul. Skwer Kard. Stefana Wyszynskiego 5/6U
01-015 Warszawa / PL
Inventor(s)01 / see applicant
...
 [2019/38]
Former [2018/42]01 / OSEKA, Maciej
Duchnów
Wspólna 16g
05-462 Duchnów / PL
Representative(s)Dargiewicz, Joanna, et al
JD&P Patent Attorneys
Joanna Dargiewicz & Partners
Ul. Mysliborska 93A/50
03-185 Warszawa / PL
[N/P]
Former [2018/42]Dargiewicz, Joanna
WTS Patent Attorneys
Witek, Sniezko & Partners
ul. Weigla 12
53-114 Wroclaw / PL
Application number, filing date16831636.209.12.2016
[2018/42]
WO2016IB57483
Priority number, datePL2015041517009.12.2015         Original published format: PL 41517015
[2018/42]
Filing languagePL
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017098461
Date:15.06.2017
Language:EN
[2017/24]
Type: A1 Application with search report 
No.:EP3386509
Date:17.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 15.06.2017 takes the place of the publication of the European patent application.
[2018/42]
Type: B1 Patent specification 
No.:EP3386509
Date:18.09.2019
Language:EN
[2019/38]
Search report(s)International search report - published on:EP15.06.2017
ClassificationIPC:A61K31/48, A61P27/02
[2018/42]
CPC:
A61K31/48 (EP,IL,RU,US); A61K9/0053 (IL,US); A61P27/02 (EP,IL,RU,US);
A61P43/00 (IL,RU)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/42]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERWENDUNG VON CABERGOLINE ZUR BEHANDLUNG VON AUGENKRANKHEITEN, DIE DURCH ERHÖHTE VASKULÄRE ENDOTHELIALE WACHSTUMSFAKTORWERTE VERURSACHT WERDEN[2019/13]
English:USE OF CABERGOLINE IN THE TREATMENT OF EYE DISEASES CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS[2019/13]
French:UTILISATION DE CABERGOLINE DANS LE TRAITEMENT DE PATHOLOGIES DE L'OEIL LIÉES À DES TAUX ÉLEVÉS DU FACTEUR DE CROISSANCE ENDOTHÉLIAL VASCULAIRE[2019/38]
Former [2018/42]VERWENDUNG VON AGONISTEN VON TYP-2-DOPAMINERGEN REZEPTOREN ZUR BEHANDLUNG VON ZUSTÄNDEN, DIE DURCH ERHÖHTE VASKULÄRE ENDOTHELIALE WACHSTUMSFAKTORWERTE VERURSACHT WERDEN
Former [2018/42]USE OF AGONISTS OF TYPE-2 DOPAMINERGIC RECEPTORS IN TREATMENT OF CONDITIONS CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS
Former [2018/42]UTILISATION D'AGONISTES DES RÉCEPTEURS DOPAMINERGIQUES DE TYPE 2 DANS LE TRAITEMENT DE PATHOLOGIES LIÉES À DES TAUX ÉLEVÉS DU FACTEUR DE CROISSANCE ENDOTHÉLIAL VASCULAIRE
Entry into regional phase09.07.2018National basic fee paid 
09.07.2018Designation fee(s) paid 
09.07.2018Examination fee paid 
Examination procedure26.04.2017Request for preliminary examination filed
International Preliminary Examining Authority: EP
05.07.2018Amendment by applicant (claims and/or description)
05.07.2018Date on which the examining division has become responsible
09.07.2018Examination requested  [2018/42]
27.03.2019Communication of intention to grant the patent
26.07.2019Fee for grant paid
26.07.2019Fee for publishing/printing paid
26.07.2019Receipt of the translation of the claim(s)
Opposition(s)19.06.2020No opposition filed within time limit [2020/35]
Fees paidRenewal fee
02.01.2019Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.12.2016
AL18.09.2019
CY18.09.2019
MC18.09.2019
MK18.09.2019
MT18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
LU09.12.2019
BG18.12.2019
IS19.01.2020
[2022/32]
Former [2021/34]HU09.12.2016
AL18.09.2019
CY18.09.2019
MC18.09.2019
MT18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
LU09.12.2019
BG18.12.2019
IS19.01.2020
Former [2021/32]HU09.12.2016
AL18.09.2019
CY18.09.2019
MC18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
LU09.12.2019
BG18.12.2019
IS19.01.2020
Former [2021/26]AL18.09.2019
CY18.09.2019
MC18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
LU09.12.2019
BG18.12.2019
IS19.01.2020
Former [2020/46]AL18.09.2019
MC18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
LU09.12.2019
BG18.12.2019
IS19.01.2020
Former [2020/39]AL18.09.2019
MC18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
BG18.12.2019
IS19.01.2020
Former [2020/37]AL18.09.2019
RO18.09.2019
RS18.09.2019
SI18.09.2019
SM18.09.2019
BG18.12.2019
IS19.01.2020
Former [2020/36]AL18.09.2019
RO18.09.2019
RS18.09.2019
SM18.09.2019
BG18.12.2019
IS19.01.2020
Former [2020/28]AL18.09.2019
RO18.09.2019
RS18.09.2019
SM18.09.2019
BG18.12.2019
IS24.02.2020
Former [2020/26]AL18.09.2019
RO18.09.2019
RS18.09.2019
BG18.12.2019
IS24.02.2020
Former [2020/23]AL18.09.2019
RO18.09.2019
RS18.09.2019
BG18.12.2019
Former [2020/15]AL18.09.2019
RS18.09.2019
BG18.12.2019
Former [2020/13]RS18.09.2019
BG18.12.2019
Former [2020/10]BG18.12.2019
Cited inInternational search[X]EP2156833  (SANTEN PHARMA CO LTD [JP]) [X] 1,2 * paragraphs [0001] , [0004] , [0006] , [0011] - [0013] - [0020] , [0029] , [0030] , [0033] , [0035] - [0040] - [0047] - [0051] * * tables 1,3 * * claims 1,4,5 *;
 [A]WO2011069051  (CALIPER LIFE SCIENCES INC [US], et al) [A] 1-9* claims 1,9,12,13 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.